Oxford biotech OMass raises $310 million for rare hormone disorder drugs
Representative image: PublicDomainPictures / Pixabay
Oxford spin-out OMass Therapeutics raised $310 million in a Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings on October 15, 2026.
What Happened
OMass Therapeutics, a drug discovery company spun out of the University of Oxford, has raised $310 million (about £230 million) in an oversubscribed Series C round, it announced on October 15, 2026. The round was co-led by three new investors, Bain Capital Life Sciences, Forbion and Novo Holdings, with Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences also joining. Every existing investor took part, including Syncona, Oxford Science Enterprises, GV, Sanofi Ventures, the British Business Bank and the University of Oxford. The money will take the company's lead drug into mid-stage trials for two rare hormone disorders.
Key Facts
- OMass Therapeutics announced a $310 million (about £230 million) Series C on October 15, 2026.
- Bain Capital Life Sciences, Forbion and Novo Holdings co-led; Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences joined, and all existing investors took part.
- Lead drug OMS1620, a melanocortin-2 receptor blocker, will move from Phase 1 to Phase 2 trials in congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.
- The money also funds a second, preclinical programme targeting lupus and other interferon-driven immune diseases.
- The round is the second-largest raised by a European biotech in 2026, after Isomorphic Labs' $2.1 billion Series B, according to industry reports.
- Chief executive Ros Deegan has said there are no immediate plans for a stock market listing.
Why It Matters
Raising $310 million in a single private round is rare for a European biotech, and it signals strong investor confidence at a time when many drug start-ups struggle to fund expensive mid-stage trials. Having three major life sciences investors lead the round, and every existing backer return, suggests they see OMass as a company that could grow into a large independent drugmaker rather than one built only to be sold early.
The company's science focuses on receptors and transporters in cell membranes, which are hard drug targets because they are difficult to study outside their natural environment. Its lead drug, OMS1620, blocks the receptor through which the hormone ACTH tells the adrenal glands to make cortisol. Both target diseases involve too much ACTH signalling, so a drug that blocks the signal at the receptor could offer a more targeted approach. The field is competitive, and reports note that OMass is racing a rival programme now owned by the US drugmaker Vertex.
For the global start-up ecosystem, the deal shows where big money is going in 2026 besides artificial intelligence: late-stage science with a clear path to patients. It also strengthens Oxford's position as one of Europe's leading sources of university spin-outs.
| Detail | OMass Series C |
|---|---|
| Amount | $310 million (about £230 million) |
| Co-leads | Bain Capital Life Sciences, Forbion, Novo Holdings |
| Lead drug | OMS1620 (melanocortin-2 receptor antagonist) |
| Target diseases | Congenital adrenal hyperplasia; ACTH-dependent Cushing's syndrome |
| Second programme | Preclinical drug for lupus and interferon-driven diseases |
Impact
Short-term: OMass will start Phase 2 trials of OMS1620 and expand its team. Evan Greif of Bain Capital Life Sciences and Audrey Cacaly of Forbion join its board. Syncona, an existing investor, said its stake will reach 16.1 per cent once the round is fully drawn down.
Long-term: Positive Phase 2 results could make OMass a contender in rare endocrine diseases and a candidate for a future listing or partnership. The round may also encourage more large investments in European biotech.
Who is affected: Patients with congenital adrenal hyperplasia, Cushing's syndrome and lupus, life sciences investors, Oxford's research ecosystem, and rival drug developers in the same field.
Key Takeaway
Oxford spin-out OMass Therapeutics' $310 million Series C, among Europe's largest biotech rounds this year, will fund Phase 2 trials of its drug for rare adrenal disorders.
Questions and Answers
How much did OMass Therapeutics raise?
OMass Therapeutics raised $310 million, about £230 million, in a Series C round announced on October 15, 2026. It was co-led by Bain Capital Life Sciences, Forbion and Novo Holdings.
What diseases is OMass targeting?
Its lead drug, OMS1620, is being developed for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, two rare hormone disorders. A second, earlier-stage drug targets lupus and other interferon-driven immune diseases.
Is OMass planning an IPO?
Chief executive Ros Deegan has said there are no immediate plans for a stock market listing.
Disclaimer: Prepared by the Peepals newsroom from publicly available sources with AI assistance. Information is accurate to the best of our knowledge at the time of publication and may change. Images may be representative. Not professional advice. Report an error via our contact page.
Sourced and fact-checked by the Peepals Global Editorial Team
Houthis claim missile hit Saudi Typhoon jet over Saada; Riyadh silent
Bhuvneshwar Kumar recalled for India's T20I decider as Arshdeep hurts shoulder
Reported, fact-checked and published by the Peepals Global Editorial Team.
